InterMune Inc. ( NASDAQ:ITMN ) reported a profit in its fourth quarter as
compared to the loss in the same period last year. This quarter results were
driven by the sale of its rights to Danoprevir to Roche, resulting $295 million
in cash and cash equivalents and provided the financial resources to
independently maximize the world-wide value of Pirfenidone. The company reported
revenue in the fourth quarter of 2010 of $241.7 million as compared with $6.6
million in the fourth quarter of 2009. For the full year, the company reported
revenue of $259.3 million as compared with $48.7 million in 2009. These results
include proceeds of $175.0 million from the sale of Danoprevir and the
accelerated recognition of approximately $57.3 million of remaining deferred
revenue in connection with the termination of the 2006 collaboration agreement
with Roche. The net income for the fourth quarter was $206.1 million, or $3.34
per diluted share as compared with a net loss of $28.6 million, or $0.62 per
diluted share, in the fourth quarter of 2009. The net income for the full year
was $122.4 million, or $2.13 per diluted share as compared with a net loss of
$116.0 million, or $2.62 per diluted share, in 2009. InterMune stock is
currently trading at $38.96. The stock is up 2.58% from its previous close.
InterMune shares touched the high of $39.33 and lowest price in today's
session is $38.51. The company stock's beta is 2.27. The company stock traded
in the range of $8.34 and $49.46 during the past 52 weeks. The company's
market cap is $2.16 billion. Cell Therapeutics Inc. ( NASDAQ:CTIC ) reported
wider loss for the fourth quarter, reflecting non-cash payment of deemed
dividends on preferred stock. The company reported net loss of $34.12 million,
or $0.04 per share as compared to $27.38 million, or $0.05 per share in the
previous year. The net operating expenses for the quarter were $16.32 million a
decrease from $26.24 million in the same quarter last year. For the full year
the company recorded net loss of 147.56 million, or $0.22 per share as compared
to $116.76 million, or $0.25 per share a year ago. The increase in net loss is
mainly due to an increase in non-cash deemed dividends on preferred stock
related to financing activities. Cell Therapeutics stock is currently trading at
$0.335. The stock is down 1.71% from its previous close. Cell Therapeutics
shares stock touched the high of $0.34 and lowest price in today's session is
$0.33. The company stock's beta is 5.93. The company stock traded in the range
of $0.12 and $1.25 during the past 52 weeks. The company's market cap is
$274.42 million. China Agritech Inc. ( NASDAQ:CAGC ) reported preliminary fourth
quarter revenues of $41 million as compared to $21 million in the same period
last year. The company reported annual revenues of $119 million as compared to
$76 million in 2009 and provides guidance of $114 million. The company
established 21 regional distribution centers this year, exceeding the original
annual goal of 10. Recently the company signed a renewed contract for supplying
organic liquid compound fertilizers to Sinochem. The sales contract is worth RMB
61 million (approximately $9 million) and the company will also continue to
supply Sinochem with organic granular compound fertilizer under another existing
contract. China Agritech stock is currently trading at $7.80. The stock is up
4.84% from its previous close. China Agritech shares stock touched the high of
$8.18 and lowest price in today's session is $7.50. The company stock's beta
is 1.85. The company stock traded in the range of $7.23 and $30.75 during the
past 52 weeks. The company's market cap is $163.62 million. Disclosure: No
position
No comments:
Post a Comment